Skip to main content

Table 1 Antibiotic course and clinical outcomes of patients who inject drugs treated with oritavancin

From: Oritavancin for the treatment of complicated gram-positive infection in persons who inject drugs

# Sex, Age range, BMI Additional Social History Infection Location, Source Control
Achieved?
Pathogen(s) Gram- Positive Antibiotics Prior to ORI (days) Abx DOT before ORI Concurrent antibiotics with ORI ORI Doses
Planned (received)
Outcome
1 M, 40–49, 22.9 Homeless BSI; SSTI
Yes
MRSA VAN × 8 8 None 1200 × 1 (1) CC
2 M, 40–49, 30.1 Homeless Joint
Yes
MRSA + Enterobacter VAN × 1 1 LVX - Enterobacter 1200 × 2 (2) CC
3 M, 40–49, 20.9 Homeless
ETOH
SSTI
N/A
Unknown None 0 None 1200 × 1 (1) CC
4 F, 40–49, 23.6 Homeless
ETOH
SSTI
N/A
MRSA VAN × 2 2 None 1200 × 1 (1) CC
5 M, 30–39, 24.5 ETOH Joint
Yes
MSSA; GAS CRO × 2
VAN × 1
2 None 1200 × 1 (1) CC
6 F, 50–59, 39.5 Homeless
ETOH
BSI; SSTI
Yes
MSSA VAN + TZP × 2
NAF × 3
CFZ ×  22
25 None 1200 × 2 (1) I/C
7 F, 40–49, 19.6 Homeless
ETOH
BSI; Bone
Yes
MSSA LVX × 1
VAN + TZP × 2
CFZ ×  24
25 None 1200 × 2 (2) CC
8 M, 40–49, 22.8 Homeless BSI; Bone;
SSTI
No
MRSA VAN × 6
DAL × 1
13 None 1200 × 1 (1) CC
9 M, 40–49, 32.2 Homeless Joint; HW
Yes
Strep mitis; Strep oralis TZP × 3
VAN × 4
CRO × 8
LVX × 8–17
36 None 1200 × 1 (1) CC
10 F, 30–39, 26.5   BSI; IE
No
MSSA VAN + TZP × 2
NAF × 2
CFZ × 16–23
VAN + TZP ×  2
CFZ × 6
30 None 1200 × 1 (1) CC
11 M, 50–59, 26.0   BSI; IE; Bone
No
MRSA VAN × 9
CPT + DAP × 14
*none × 4 days*
CPT × 5
DAP ×  22
47 None 1200 × 2 (2) F
12 F, 30–39, 32.5 Homeless BSI
N/A
MSSA CRO × 2
VAN × 3
CFZ ×  15
None ×  2
CFZ ×  2
20 None 1200 × 1 (1) CC
13 M, 40–49, 34.1 Homeless BSI
N/A
MSSA VAN × 3
CFZ × 7
CRO × 1
10 None 1200 × 1 (1) LTFU
14 M, 30–39, 28.9 Homeless
ETOH
BSI; SSTI
N/A
MRSA VAN × 15
DAP ×  1
16 None 1200 × 2 (2) LTFU
15 M, 60–69, 44.6   Joint; HW
No
MRSA, MRSE VAN × 6
DOX × 5
VAN × 4
13 None 1200 × 1 (1)
800 × 5 (5)
CC
16 F, 20–29, 24.2 Homeless
ETOH
Bone
No
MRSA VAN × 1 1 None 1200 × 2 (2) I/C
17 M, 20–29, 22.1 Homeless Bone; HW
No
MSSA VAN + TZP × 2
CFZ × 2
3 RIF 1200 × 2 (2) CC
18 M, 30–39, 19.6 Homeless
ETOH
Bone; SSTI
Yes
MRSA VAN × 5
DOX × 2
7 DOX 1200 × 2 (1) I/C
19 F, 30–39, 36.2   BSI; Bone No MRSA VAN × 9 9 None 1200 × 4 (3) I/C
20 F, 20–29, 23.0   Bone
No
MRSA VAN × 13 13 None 1200 × 1 (1)
800 × 3 (1)
I/C
21 M, 20–29, 23.4   BSI; SSTI
N/A
MSSA VAN × 2
CFZ × 4
4 None 1200 × 2 (1) I/F
22 M, 40–49, 32.2 Homeless Joint
Yes
MRSA VAN × 2 2 RIF 1200 × 1 (1)
800 × 5 (5)
CC
23 M, 30–39, 22.8 ETOH BSI
N/A
MRSA VAN × 6 6 None 1200 × 1 (1) F
24 M, 60–69, 18.0 Homeless Bone
No
MRSA DAP × 4 4 None 1200 × 1 (1)
800 × 3 (3)
CC
  1. Heading abbreviations: Abx antibiotic, BMI body mass index, DOT days of therapy
  2. Social history abbreviations: ETOH ethanol
  3. Infection location abbreviations: BSI bloodstream infection, HW hardware, IE infective endocarditis, SSTI skin and soft tissue infection
  4. Pathogen abbreviations: GAS group A strep, MRSA methicillin resistant staph aureus, MSSA methicillin susceptible staph aureus, MRSE methicillin resistant staph epidermidis
  5. Antimicrobial abbreviations:CFZ cefazolin, CRO ceftriaxone, FEP cefepime, CPT ceftaroline, DAL dalbavancin, DAP daptomycin, DOX doxycycline, LVX levofloxacin, LZD linezolid, MTZ metronidazole, MEM meropenem, NAF nafcillin, ORI oritavancin, TZP piperacillin-tazobactam, RIF rifampin, SXT trimethoprim-sulfamethoxazole, VAN vancomycin
  6. Treatment evaluation outcomes: CC clinical cure, F failure, I/C incomplete (patient didn’t adhere to intended regimen but appears to have been cured), I/F incomplete adherence and clinical failure, LTFU lost to follow up